What If We Are Funding Biotech the Wrong Way?
Biotech is often described as capital intensive, high risk, and slow to mature. Those statements are all true, but they are also incomplete. What we are seeing now is not simply the consequence of a difficult sector. It is the result of a deeper misalignment between the nature of scientific…